Theralase Technologies Inc. V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:Scientists harness light therapy to target and kill cancer c

[Pandora]

Pandora wrote:

Pandora wrote:

CancerSlayer wrote:

It appears they are also still at the preclinical stages in reference to GBM (no humans tested).  But I also noted in the article that the European scientists were also very concerned about how to overcome the technical challenges of reaching deep-seated or less accessible solid tumors (like GBM) with near-infrared light.  The scientists were "excited to see how this research will develop".  Well, it looks like TLT may already have the advantage & answer to this technical challenge with its patented "x-ray activated" PDCs for destroying cancer.  

Perhaps our in-house patent expert, Pandora, could elaborate on this...does the patent extend to all forms of radiotherapy?

I'm not good in looking at European stuff. Could not find anything in the USPTO files and the Google patent search doesn't appear to show anything other than Theralase that is less than 10 years old other than one from 2017 that was abandoned.

However I did find one in the USPTO that is interesting:

---

Light-activated compounds

Abstract

The presently-disclosed subject matter includes light-activated ruthenium compounds. In some embodiments the compounds release one or more ligands when exposed to light, and in specific embodiments the light includes a wavelength of about 500 nm to about 1000 nm. The present compounds can also comprise an overall charge, wherein the overall charge can be a positive overall charge or a negative overall charge. Further still, embodiments include methods of treating cancer in a subject by administering a compound and then exposing a site of the subject to light.

---

Inventors:

Glazer; Edith C. (Lexington, KY), Heidary; David K. (Lexington, KY)

Applicant:

Name	City	State	Country	Type

United States Patent	9,290,528
Glazer ,   et al.	March 22, 2016

Looking at the references -- and there are hundreds - I did spot McFarland, S.A. Inorg. Chem. 2010

and upon Googling that I pulled up this:

Scholarly articles for McFarland, S. A., Inorg. Chem. 2010, 49 (6), 2889-900

Photochemical and photobiological activity of Ru (II) … - ‎Kohler - Cited by 49

and from that:

Photochemical and Photobiological Activity of Ru(II) Homoleptic and Heteroleptic
Complexes Containing Methylated Bipyridyl-type Ligands

Lars Kohler , a Leona Nease, b Pascal Vo, a Jenna Garofolo, b David K. Heidary, a

Randolph P. Thummel, a * and Edith C.Glazer

Department of Chemistry, 112 Fleming Building, University of Houston, Houston, TX

77204-5003

b

Department of Chemistry, University of Kentucky, Lexington, KY 40506

This article is cited by 33 publications: (first of which is)

1. John A. Roque III, Houston D. Cole, Patrick C. Barrett, Liubov M. Lifshits, Rachel O. Hodges, Susy Kim, Gagan Deep, Antonio Francs-Monerris, Marta E. Alberto, Colin G. Cameron, Sherri A. McFarland. Intraligand Excited States Turn a Ruthenium Oligothiophene Complex into a Light-Triggered Ubertoxin with Anticancer Effects in Extreme Hypoxia. Journal of the American Chemical Society 2022, 144 (18) , 8317-8336. https://doi.org/10.1021/jacs.2c02475

And if you click on this above  link and go through to the references you will find Reference Number 29:
Not sure why it doesn't post/format properly:

   

(29) Monro, S.; Coln, K. L.; Yin, H.; Roque, J.; Konda, P.; Gujar, S.; Thummel, R. P.; Lilge, L.;

Cameron, C. G.; McFarland, S. A. Transition Metal Complexes and Photodynamic Therapy

from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the

Development of TLD1433.

Chem. Rev.

2019

,

119

(2), 797–828.

https://doi.org/10.1021/acs.chemrev.8b00211